预约演示
更新于：2025-08-26
Tobramycin Sulfate
硫酸妥布霉素
更新于：2025-08-26
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1975-06-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H39N5O13S |
InChIKeyZEUUPKVZFKBXPW-TWDWGCDDSA-N |
CAS号49842-07-1 |
关联
6
项与 硫酸妥布霉素 相关的临床试验NCT04662632
A Randomized Controlled Trial of Alternating Irrigation of Vancomycin Hydrochloride and Tobramycin Sulfate in Patients Undergoing Two-Stage Exchange Arthroplasty for Periprosthetic Joint Infection (PJI) of the Hip or Knee
NCT03066453
Evaluation of an Antibiotic Treatment With 14 Days of Intravenous Tobramycin Versus the Same Antibiotic Associated With 5 Days of Intravenous Tobramycin Followed by Tobramycin Aerosol for 9 Days in Cystic Fibrosis.
NCT01431326
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
100 项与 硫酸妥布霉素 相关的临床结果
登录后查看更多信息
100 项与 硫酸妥布霉素 相关的转化医学
登录后查看更多信息
100 项与 硫酸妥布霉素 相关的专利（医药）
登录后查看更多信息
9,857
项与 硫酸妥布霉素 相关的文献（医药）2025-12-31Virulence
Physiological role of bicarbonate in microbes: A double-edged sword?
Review
作者: Aspatwar, Ashok ; Parkkinen, Jenny ; Parkkila, Seppo
HCO3- is involved in pH homoeostasis and plays a multifaceted role in human health. HCO3- has been recognized for its antimicrobial properties and is pivotal in bacterial antibiotic susceptibility. Notably, the interconversion between CO2 and HCO3-, facilitated by the enzyme carbonic anhydrase (CA), is crucial in tissues infected by pathogens. Studies have highlighted the antimicrobial potency of CA inhibitors, emphasizing the importance of this enzyme in this area. The potential of HCO3- as an antibiotic adjuvant is evident; its ability to increase virulence in pathogens such as Enterococcus faecalis and Mycobacterium tuberculosis requires meticulous scrutiny. HCO3- modulates bacterial behaviours in diverse manners: it promotes Escherichia coli O157:H7 colonization in the human gut by altering specific gene expression and, with Pseudomonas aeruginosa, amplifies the effect of tobramycin on planktonic cells while promoting biofilm formation. These multifaceted effects necessitate profound mechanistic exploration before HCO3- can be considered a promising clinical adjuvant.
2025-12-01MOLECULAR BIOLOGY REPORTS
Targeted inhibition of PqsR in Pseudomonas aeruginosa PAO1 quorum-sensing network by chalcones as promising antibacterial compounds
Article
作者: Soheili, Vahid ; Tajani, Amineh Sadat ; Bazzaz, Bibi Sedigheh Fazly ; Rezaei, Tahoura ; Hashemi, Maryam ; Ghodsi, Razieh ; Arami, Negin
BACKGROUND:
Pseudomonas aeruginosa's inherent and adapted resistance makes this pathogen a serious problem for antimicrobial treatments. Furthermore, its biofilm formation ability is the most critical armor against antimicrobial therapy, and the virulence factors, on the other hand, contribute to fatal infection and other recalcitrant phenotypic characteristics. These capabilities are harmonized through cell-cell communication called Quorum Sensing (QS), which results in gene expression regulation via three major interconnected circuits: las, rhl, and pqs system. Pqs circuit specificity in P. aeruginosa made this system an attractive target for antipseudomonal therapy. The current study focuses on novel chalcone derivatives that attenuate P. aeruginosa's pathogenicity by inhibiting the QS system. Chalcones are included in the flavonoid class of phenolic compounds. This family forms one of the greatest groups of bioactive natural products.
METHOD:
The chalcone derivatives's potential activity against the QS system was evaluated through biofilm inhibition, decreased virulence factors production, and gene expression.
RESULTS:
Among all the tested compounds, 5H and NMe2 chalcone derivatives reduced biofilm formation by 60.9% and 78.9%, respectively, and virulence factors production, including pyocyanin (decreased by 5H 30.9% and NMe2 30.7%) and pyoverdine (decreased by 5H 47.1% and NMe2 56.9%) and the QS gene expression (LasR, RhlR, and PqsR) more effectively than other derivatives.
CONCLUSION:
These chalcone compounds can be used as a supplement besides antimicrobial chemotherapy to attenuate pseudomonas pathogenicity.
2025-11-01SENSORS AND ACTUATORS B-CHEMICAL
Revealing the impact of temperature on electrochemical, DNA-based sensors to correct signaling fluctuations
作者: Lobo-Castanon, Maria Jesus ; Sfragano, Patrick Severin ; de-los-Santos-Alvarez, Noemi ; Pellitero, Miguel Aller
Developing convenient and easy-to-use anal. tools for real-world applications requires sensing approaches that enable rapid, reagentless, and in situ quantitation of diverse mol. targets.Electrochem., DNA-based (E-DNA) sensors meet these needs by utilizing conformational changes in electrode-bound, redox reporter-modified DNA probes upon target binding.The recognition event alters the electron transfer rate from the redox reporter, which can be monitored using square wave voltammetry by synchronizing the excitation frequency with the charge transfer rate.However, the kinetic nature of the surface-bound sensing process makes signaling strongly temperature-dependent, an aspect that has been widely overlooked and that restricts the application of E-DNA sensors to temperature-controlled environments.Here, we explore the relationship between electrochem. signal, square wave frequency, and temperature across different DNA constructs.Doing so, we identified the architectures most susceptible to temperature-induced signal fluctuations and developed two straightforward correction strategies.These approaches are particularly effective for electrochem., aptamer-based (E-AB) sensors, enabling accurate and stable measurements over a wide temperature range, from 22°C to 37°C.By eliminating the significant influence of temperature on signaling, we broaden the applicability of E-DNA sensors, enhancing their performance for point-of-care testing, continuous mol. monitoring, and other real-world scenarios where temperature fluctuations are unavoidable.
100 项与 硫酸妥布霉素 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 囊性纤维化 | 澳大利亚 | 2009-07-17 | |
| 下呼吸道感染 | 美国 | 2004-07-13 | |
| 脑膜炎 | 美国 | 2004-07-13 | |
| 腹膜炎 | 美国 | 2004-07-13 | |
| 脓毒症 | 美国 | 2004-07-13 | |
| 皮肤和皮肤结构感染 | 美国 | 2004-07-13 | |
| 泌尿道感染 | 美国 | 2004-07-13 | |
| 细菌感染 | 美国 | 1975-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | Tobramycin nebulization solution 300 mg/4 ml (TNS4) | 憲衊淵艱壓選築鑰鹽衊(蓋顧範觸窪鏇觸膚構構) = 夢構鏇醖糧窪衊願製製 繭簾夢糧選夢衊簾餘繭 (觸遞憲齋憲顧構構壓淵 ) 更多 | - | 2014-11-01 | ||
Tobramycin 300 mg/5 ml (TNS5) | 憲衊淵艱壓選築鑰鹽衊(蓋顧範觸窪鏇觸膚構構) = 淵遞膚範遞艱網簾網鑰 繭簾夢糧選夢衊簾餘繭 (觸遞憲齋憲顧構構壓淵 ) | ||||||
临床3期 | 324 | (Bramitob) | 淵醖範鹽鏇糧襯衊顧獵(襯顧窪艱廠夢醖遞廠齋) = 鏇鏇築醖簾觸簾艱淵積 願蓋夢壓衊淵糧鑰築膚 (遞襯糧窪願製構鹹齋顧, 9.52) 更多 | - | 2014-06-20 | ||
(TOBI) | 淵醖範鹽鏇糧襯衊顧獵(襯顧窪艱廠夢醖遞廠齋) = 夢築願齋築選鏇願築積 願蓋夢壓衊淵糧鑰築膚 (遞襯糧窪願製構鹹齋顧, 9.63) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用